研究报告 Research Report 6 Jun 2025 阿里健康 AliHealth (241 HK) FY3/25 财年收入略超市场预期，并表广告业务增厚利润 FY3/25 Revenue Slightly Beat, with the Inclusion of Advertising Business Boosting Profits [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$4.50 目标价 HK$5.42 HTI ESG 4.0-4.0-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$72.56bn / US$9.25bn 日交易额 (3 个月均值) US$70.20mn 发行股票数目 16,124mn 自由流通股 (%) 31% 1 年股价最高最低值 HK$6.15-HK$2.75 注：现价 HK$4.51 为 2025 年 06 月 02 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovation-driven pharmaceutical enterprise, focusing on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It is projected to achieve a revenue of HKD 12.26 billion in 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with a strong pipeline that is expected to drive future growth. The sales of innovative drugs are anticipated to continue increasing, with a projected revenue of HKD 9.477 billion in 2024, marking a 38.1% year-on-year growth [16][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system, employing over 1,800 professionals and creating several national-level research institutions. It has been recognized as a key high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethylnitro (甲磺酸氟马替尼片), which are expected to contribute significantly to revenue growth [16][17]. 2. Market Performance - The sales of Amelotin, the first domestic third-generation EGFR TKI, are projected to grow rapidly, with a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales of third-generation EGFR TKIs by 2024 [2]. - The company has also seen significant sales growth in Fluoromethylnitro, with a 54% increase in 2023 and a projected 36% growth in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence through collaborations, such as granting global exclusive licensing rights for HS-10535 to Merck, indicating strong potential for future revenue streams [4][5]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion, respectively, with net profits expected to reach HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

2025 年 06 月 06 日 公司深度研究 买入/首次 天立国际控股(01773) 目标价: 昨收盘:4.42 K12 民办教育领军者，多元化升学加速成长 ◼ 走势比较 (30%) (16%) (2%) 12% 26% 40% 24/6/6 24/8/17 24/10/28 25/1/8 25/3/21 25/6/1 天立国际控股 ◼ 股票数据 总股本/流通(亿股) 21.06/21.06 总市值/流通(亿港元) 93.1/93.1 12 个月内最高/最低价 (港元) 5.98/3.1 相关研究报告 证券分析师：王湛 电话： E-MAIL：wangzhan@tpyzq.com 分析师登记编号：S1190517100003 报告摘要 天立国际控股作为国内领先的 K12 民办教育集团，自 2002 年成 立以来，历经扎根四川完善 K12 体系、跨区域扩张成西部龙头、政策 驱动下聚焦高中与轻资产转型、全国校网成型与数字化双轮驱动等阶 段。截至 2024 年 11 月，公司已在 18 个省市运营 58 所学校，服务在 校生超 13 万人，其中高中生 5.39 万人，形成以高中教育为核心、多 元业务协同发展的教育生 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovative pharmaceutical enterprise with a focus on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It has shown robust performance with a projected revenue of HKD 12.26 billion for 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with significant sales growth in its key products, particularly in the oncology sector, which is expected to account for 66.24% of total revenue by 2024 [17][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system with over 1,800 professional researchers, focusing on drug discovery and clinical research. It has been recognized as a national high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethine (甲磺酸氟马替尼片), which have shown strong sales performance [16][17]. 2. Sales Performance - The sales of Amelotin are projected to grow at a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales for third-generation EGFR TKIs by 2024 [2]. - The sales of Fluoromethine increased by 54% in 2023 compared to the previous year, with a projected growth of 36% in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence with global licensing agreements for its innovative drugs, indicating strong potential for future revenue growth [4][5]. 4. Financial Forecast - The revenue forecast for the company is set at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion for the years 2025, 2026, and 2027, respectively, with net profits projected at HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

研究报告 Research Report 6 Jun 2025 阿里健康 AliHealth (241 HK) FY3/25 财年收入略超市场预期，并表广告业务增厚利润 FY3/25 Revenue Slightly Beat, with the Inclusion of Advertising Business Boosting Profits [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$4.50 目标价 HK$5.42 HTI ESG 4.0-4.0-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$72.56bn / US$9.25bn 日交易额 (3 个月均值) US$70.20mn 发行股票数目 16,124mn 自由流通股 (%) 31% 1 年股价最高最低值 HK$6.15-HK$2.75 注：现价 HK$4.51 为 2025 年 06 月 02 ...

| 华泰研究 | | | 更新报告 | | --- | --- | --- | --- | | 2025 年 | 6 月 | 06 日│中国香港 | 发电 | 6 月 5 日中电控股出席了我们组织的 2025 年中期策略会，会上公司分享近 期经营变化和后续展望。我们认为主要关注点包括：1）稳定型业务：随资 本投入转固，管制业务利润贡献或稳步增厚；Q1 中国内地核电机组稳健运 行，阳江核电站电价略有下滑。2）成长型业务：Q1 中国内地、印度多个 零碳项目顺利投产，零碳项目投资计划的落地或为公司业绩注入成长潜力。 稳定型业务：Q1 中国香港售电量同比-2.6%，中国内地核电资产稳健运行 据公司公告，受天气和暖、2024 年为闰年等因素影响，虽数据中心等新兴 行业用电需求增长，Q1 中国香港售电量 70.91 亿度，同比-2.6%。但考虑 到现行管制计划协议约定公司电力业务实现的准许利润占固定资产净额的 比例为 8%，我们依旧看好在高确定性资本开支（2024-28 年预计 529 亿港 元）的保障下，随资本投入不断转固，利润贡献或稳步增厚。核电业务方面， 受益于停运天数减少，Q1 大亚湾核电站发电量同比增加；广东省 ...

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company is optimistic about long-term aluminum prices and has a strong dividend profile, which supports the investment thesis [1][2] - The planned acquisition of 100% equity in Hongtuo Industrial by the holding company Hongchuang Holdings is expected to enhance the company's market influence and asset securitization level [2] - The decline in energy prices is anticipated to reduce costs, while the upcoming production of the Simandou iron ore project is expected to contribute positively to the company's performance [3] Summary by Sections Acquisition and Restructuring - Hongchuang Holdings plans to issue shares to acquire 100% of Hongtuo Industrial for approximately 635.18 billion RMB, which will slightly dilute the company's shareholding from 95.30% to about 88.99% [2] Cost and Production Outlook - The average coal price at Qinhuangdao Port for the first five months of 2025 was 703 RMB/ton, down from 872 RMB/ton in 2024, which is expected to lower electricity costs in Shandong [3] - The Simandou iron ore project is expected to commence production by the end of 2025, with a designed capacity of 60 million tons per year [3] Aluminum Price and Profitability - Short-term demand for electrolytic aluminum may face seasonal declines, but supply constraints and high demand in sectors like new energy vehicles are expected to keep prices stable [4] - The company forecasts a gradual increase in aluminum prices from 2025 to 2026, with a projected net profit of 161.29 billion RMB in 2025 [5] Financial Projections - The company’s projected net profits for 2025, 2026, and 2027 are 161.29 billion RMB, 177.51 billion RMB, and 212.85 billion RMB respectively [5] - The target price is set at 15.37 HKD, with a historical average PE ratio of 7.03X since 2017 [5][9]

越疆（02432.HK） 与药师帮签署战略合作协议，越疆机器人率 先落地医药应用场景 证券研究报告·海外公司点评·软件服务(HS) 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 286.75 | 373.68 | 496.41 | 672.80 | 896.94 | | 同比(%) | 18.98 | 30.32 | 32.84 | 35.53 | 33.32 | | 归母净利润（百万元） | (103.28) | (95.36) | (43.49) | 1.15 | 34.54 | | 同比(%) | (96.81) | 7.67 | 54.40 | 102.65 | 2,893.76 | | EPS-最新摊薄（元/股） | (0.26) | (0.24) | (0.11) | 0.00 | 0.09 | | P/E（现价&最新摊薄） | (219.45) | (237.67) | (521.19) | 19 ...

Investment Rating - The report maintains a "Buy" rating for the company, Sihuan Pharmaceutical (02096), with a target price of HKD 14.3, and continues to recommend it as a key focus in the industry [1]. Core Insights - The report has raised the profit forecast for the company for the years 2025-2027 by 6-11% and is optimistic about the potential for more overseas transactions in the short term, particularly focusing on targets such as CDH6 and CDH17, which have recently garnered significant attention [1]. - At the ASCO 2025 conference, the company's oncology pipeline showcased 18 research studies. Key studies to watch include: 1. The final analysis of overall survival (OS) in a Phase III study of Suviscita monoclonal antibody for platinum-resistant ovarian cancer, with median OS of 15.3 months for the treatment group compared to 14 months for the control group, with approval expected within the year [1]. 2. The results of an Ib phase study on SIM0270 combined with Palbociclib for second-line or higher ER+/HER2- breast cancer, showing an overall response rate (ORR) of 41.5% and clinical benefit rate (CBR) of 82.5%, with rates of 87.5% and 100% respectively in baseline ESR1 mutation patients. The company is currently conducting a Phase III study to evaluate the efficacy of SIM0270 combined with Everolimus in CDK4/6 inhibitor-treated ER+/HER2- breast cancer [1].

Investment Rating - The report maintains a "Buy" rating for the company Gu Ming (01364) [1] Core Insights - Gu Ming has achieved a same-store sales growth of approximately 10% this year, with store opening plans reaching 1,500 to 2,000, exceeding previous estimates [1] - UBS has raised the target price for Gu Ming from HKD 19.28 to HKD 31.15, corresponding to forecasted P/E ratios of 34x and 27x for 2025 and 2026 respectively [1] - The current valuation of Gu Ming is considered attractive at 1.3x dynamic P/E compared to the industry average of 1.9x [1] - The management has reiterated a long-term goal of reaching 30,000 stores by 2030, supporting an estimated annual store growth of about 20% [1] Financial Projections - UBS has increased the earnings per share forecast for Gu Ming for 2025 to 2027 by 6% to 11%, driven by a revenue forecast increase of 6% to 12%, reaching RMB 11.5 billion, RMB 14.1 billion, and RMB 17.2 billion respectively [2] - Same-store sales are expected to grow by 6% in 2025, supported by the introduction of coffee beverages [2]